GlassScriptPhysician profile
James M Watkins
NPI 1740546381
$11,352.33
in general payments reported to CMS, 2019-2025
62 companies · $1,654 in 2025
The $1,654 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,667 · 2020: $1,395 · 2021: $1,822 · 2022: $1,842 · 2023: $1,734 · 2024: $1,238 · 2025: $1,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,626.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,715.37 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $971.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $843.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $819.51 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $616.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $579.99 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $440.13 | 2019-2025 | Farxiga |
| Amgen INC. | $409.95 | 2019-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $388.92 | 2019-2024 | Belsomra, Verquvo, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $353.27 | 2019-2022 | |
| Antares Pharma, INC. | $337.15 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Kowa Pharmaceuticals America, INC. | $320.21 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Esperion Therapeutics, INC. | $287.00 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $211.26 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $201.50 | 2019-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.